Our findings are supported by previous studies, indicating that CSF3 expression, and consequently the production of G-CSF, is associated not only with tumor progression but also with chemoresistance in NSCLC patients treated with the Car plus Pac doublet regimen. Here, CSF3 is linked to neoplasm.